Italia markets open in 2 hours 41 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
162,48+2,13 (+1,33%)
Alla chiusura: 04:00PM EDT
162,35 -0,13 (-0,08%)
Dopo ore: 06:18PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente160,35
Denaro161,60 x 1000
Lettera162,34 x 900
Min-Max giorno160,44 - 163,50
Intervallo di 52 settimane117,08 - 388,00
Media Volume1.086.958
Beta (5 anni mensile)-0,08
Rapporto PE (ttm)3,48
EPS (ttm)46,63
Prossima data utili07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo02 giu 2022
Stima target 1A240,07
  • GlobeNewswire

    BioNTech Announces Second Quarter Financial Results and Corporate Update

    Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well as first half 2022 revenues of €9.6 billion, net profit of €5.4 billion and fully diluted earnings per share of €20.69 ($18.922)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of €13 billion to €17 billionPreparing for potential launch of two variant-adapted bivalent COVID-19 vaccines containing the original strain and Omicron BA.1 or BA.4/5 spike protein

  • GlobeNewswire

    BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

    Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform to develop novel immunotherapies First monospecific antibody candidate GEN1053/BNT313 planned to enter clinical trials by the end of 2022 BioNTech and Genmab will share costs and potential future profits on a 50:50 basis MAINZ, Germany, and COPENHAGEN, Denmark, August 5, 2022 – BioNTech SE (Nasdaq: B

  • GlobeNewswire

    Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design

    NEW YORK and MAINZ, Germany, July 27, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestr